321 results on '"Hansen, Doris"'
Search Results
102. 256 - Baseline Levels of Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel
103. 245 - Fludarabine Exposure Impact on Safety and Efficacy of Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma (RRMM)
104. 140 - Impact of Obesity and Chemotherapy Dosing on Allogeneic Hematopoietic Cell Transplant Outcomes for Myelodysplastic Syndrome (MDS)
105. 42 - Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) with Renal Impairment: Real World Experience
106. Impact of doxycycline on outcomes in AL amyloidosis.
107. Will adding alkylating agent to bortezomib improve survival of newly diagnosed AL amyloidosis patients?
108. 451 - Cytopenia and Infection Early after Standard of Care Idecabtagene Vicleucel in Multiple Myeloma
109. 403 - CD40 Ligand Blockade Prevents Acute Gvhd: Results from a Multicenter Phase I-Ib Trial
110. 405 - Prospective Cohort Study of Immune Suppression Taper and Discontinuation
111. 241 - Marrow Myeloma Burden and Idecabtagene Vicleucel Outcomes in the Standard of Care Setting
112. 243 - Impact of Obesity on Lymphodepletion and Outcomes Following Idecabtagene Vicleucel in Multiple Myeloma
113. 167 - Measurable Residual Disease Outcompetes Cytogenetics in Predicting Leukemia Free Survival Following Allogeneic Stem Cell Transplantation Outcomes in Adults with Acute Lymphoblastic Leukemia
114. ELN 2017 Risk Classification Predicts Survival of AML Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
115. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma Immunotherapy Consortium Real World Experience
116. Applying the EHA/EBMT Grading for ICAHT after CAR-T: Comparative Incidence and Association with Infections and Mortality
117. Autologous Bone Marrow Transplantation for Multiple Myeloma: An Analysis of Risk Factors that Affected Patient Outcomes at the University of Mississippi Medical Center.
118. Paired Analysis from Patients with Myeloma Elucidates Favorable CAR-T Manufacture and Phenotype, Starting from Mobilized Pre-Transplant Apheresis Vs. Non-Mobilized Apheresis after Four Prior Lines
119. A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
120. Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
121. A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel
122. Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma
123. Unveiling the Digital Landscape of CAR-T Therapies in Multiple Myeloma Using Social Media Insights
124. Clinician and Administrator Perspectives on Chimeric Antigen Receptor (CAR) T-Cell Therapy Outpatient Administration in Relapsed or Refractory Multiple Myeloma (RRMM) in the United States (US): A Qualitative Study
125. Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality
126. Expression of Cell Surface Immunotherapy Targets across the Multiple Myeloma Disease Spectrum: Implications for Sequencing and Multi-Target Strategies
127. Cost per Responder Analysis of Patients with Lenalidomide-Refractory Multiple Myeloma Who Received Cilta-Cel from the Cartitude-4 Trial
128. Facility-Related Healthcare Resource Utilization (HCRU) for Patients Treated with Idecabtagene Vicleucel (Ide-Cel, bb2121) in a Real-World (RW) Setting: A Single-Center Experience
129. Single Cell RNA Sequencing of Sequential Samples before and after BCMA-Directed CAR-T Reveal Features Associated with Non-Durable Response, Exhausted T-Cells and Decreased Expression of Genes Encoding Key Surface Targets in Particular in Patients with Extramedullary Disease
130. Selinexor Disrupts Epigenetic Programing and Modulates Immunogenicity in Multiple Myeloma
131. A Novel Composite Endpoint of Toxicity- and Progression-Free Survival after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma
132. Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma
133. Teclistamab Induces Favorable Responses in Patients with Relapsed and Refractory Multiple Myeloma after Prior BCMA-Directed Therapy
134. The 2022 Ladie's Tour.
135. Association of venetoclax-based therapy with increased survival in multiple myeloma (MM) harboring t(11;14): A single-center experience.
136. Experience of a stem cell transplant in multiple myeloma: The patient and care partner perspective.
137. Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium.
138. Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).
139. Association of frailty and high-risk immuno-nutritional score with outcomes in patients with relapsed and refractory multiple myeloma treated with chimeric antigen receptor T-cells.
140. Sporopachydermia cereana Sepsis in a Patient With Acute Myeloid Leukemia
141. The 2023 Ladies' Tour.
142. A Case of Metastatic Melanoma of the Heart Diagnosed Antemortem.
143. Carbonic Anhydrase in Congenital Heart Disease.∗.
144. Sporopachydermia cereanaSepsis in a Patient With Acute Myeloid Leukemia
145. Increased Infections and Delayed CD4+T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation
146. The 2017 Ladie's Tour.
147. Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature.
148. 2015 Ladies' Tour.
149. Über die Notwendigkeit, bei der Beurteilung von Übersetzungsqualität Linguistik zu betreiben
150. Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.